Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option.
Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531
JC Companion: https://autoimmunedevreport.substack.com/
